Rein Long Term Debt vs Intangible Assets Analysis

RNTX Stock   1.17  0.10  7.87%   
Rein Therapeutics financial indicator trend analysis is much more than just breaking down Rein Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Rein Therapeutics is a good investment. Please check the relationship between Rein Therapeutics Long Term Debt and its Intangible Assets accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rein Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy Rein Stock please use our How to Invest in Rein Therapeutics guide.

Long Term Debt vs Intangible Assets

Long Term Debt vs Intangible Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Rein Therapeutics Long Term Debt account and Intangible Assets. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Rein Therapeutics' Long Term Debt and Intangible Assets is 0.9. Overlapping area represents the amount of variation of Long Term Debt that can explain the historical movement of Intangible Assets in the same time period over historical financial statements of Rein Therapeutics, assuming nothing else is changed. The correlation between historical values of Rein Therapeutics' Long Term Debt and Intangible Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Long Term Debt of Rein Therapeutics are associated (or correlated) with its Intangible Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Intangible Assets has no effect on the direction of Long Term Debt i.e., Rein Therapeutics' Long Term Debt and Intangible Assets go up and down completely randomly.

Correlation Coefficient

0.9
Relationship DirectionPositive 
Relationship StrengthVery Strong

Long Term Debt

Long-term debt is a debt that Rein Therapeutics has held for over one year. Long-term debt appears on Rein Therapeutics balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Rein Therapeutics balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.

Intangible Assets

Non-physical assets possessed by a company, such as patents, trademarks, and copyrights, which provide long-term value.
Most indicators from Rein Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Rein Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rein Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy Rein Stock please use our How to Invest in Rein Therapeutics guide.At this time, Rein Therapeutics' Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to rise to about 13.1 M in 2025, despite the fact that Tax Provision is likely to grow to (1.5 M).
 2022 2023 2024 2025 (projected)
Reconciled Depreciation169K119K63K101.6K
Total Operating Expenses27.6K16.3K65.1K34.3K

Rein Therapeutics fundamental ratios Correlations

0.660.640.67-0.05-0.61-0.710.310.640.82-0.120.51-0.250.370.74-0.320.52-0.570.69-0.6-0.63-0.27-0.680.020.65-0.27
0.660.910.750.42-0.26-0.640.260.40.51-0.390.43-0.490.420.7-0.610.44-0.590.46-0.34-0.35-0.44-0.40.020.45-0.44
0.640.910.820.48-0.36-0.680.610.530.41-0.560.59-0.640.570.77-0.710.6-0.650.45-0.39-0.39-0.38-0.390.060.4-0.38
0.670.750.820.2-0.19-0.830.490.260.42-0.690.67-0.850.720.93-0.910.68-0.680.68-0.69-0.68-0.45-0.640.260.64-0.45
-0.050.420.480.20.340.050.33-0.03-0.130.030.06-0.390.140.11-0.310.07-0.25-0.260.320.330.170.29-0.08-0.280.17
-0.61-0.26-0.36-0.190.340.38-0.42-0.94-0.590.09-0.27-0.21-0.01-0.25-0.11-0.260.33-0.310.320.350.360.350.28-0.280.36
-0.71-0.64-0.68-0.830.050.38-0.32-0.36-0.680.63-0.330.53-0.53-0.920.66-0.340.82-0.910.910.920.630.88-0.15-0.840.63
0.310.260.610.490.33-0.42-0.320.58-0.03-0.50.63-0.550.490.48-0.480.63-0.350.18-0.24-0.220.07-0.120.10.090.07
0.640.40.530.26-0.03-0.94-0.360.580.56-0.070.310.10.070.310.030.31-0.420.24-0.22-0.25-0.24-0.25-0.320.18-0.24
0.820.510.410.42-0.13-0.59-0.68-0.030.560.08-0.010.070.080.52-0.06-0.01-0.70.61-0.57-0.61-0.53-0.65-0.30.56-0.53
-0.12-0.39-0.56-0.690.030.090.63-0.5-0.070.08-0.50.73-0.64-0.640.8-0.520.37-0.520.60.560.460.45-0.44-0.510.46
0.510.430.590.670.06-0.27-0.330.630.31-0.01-0.5-0.640.580.55-0.61.0-0.020.31-0.29-0.280.0-0.320.550.40.0
-0.25-0.49-0.64-0.85-0.39-0.210.53-0.550.10.070.73-0.64-0.76-0.740.97-0.660.44-0.390.460.410.140.31-0.4-0.340.14
0.370.420.570.720.14-0.01-0.530.490.070.08-0.640.58-0.760.67-0.730.61-0.410.43-0.6-0.5-0.12-0.310.490.38-0.12
0.740.70.770.930.11-0.25-0.920.480.310.52-0.640.55-0.740.67-0.80.57-0.750.85-0.83-0.82-0.35-0.760.250.76-0.35
-0.32-0.61-0.71-0.91-0.31-0.110.66-0.480.03-0.060.8-0.60.97-0.73-0.8-0.610.54-0.50.540.520.340.42-0.34-0.450.34
0.520.440.60.680.07-0.26-0.340.630.31-0.01-0.521.0-0.660.610.57-0.61-0.030.32-0.31-0.290.0-0.330.550.40.0
-0.57-0.59-0.65-0.68-0.250.330.82-0.35-0.42-0.70.37-0.020.44-0.41-0.750.54-0.03-0.60.660.660.530.530.31-0.430.53
0.690.460.450.68-0.26-0.31-0.910.180.240.61-0.520.31-0.390.430.85-0.50.32-0.6-0.93-0.95-0.41-0.950.330.94-0.41
-0.6-0.34-0.39-0.690.320.320.91-0.24-0.22-0.570.6-0.290.46-0.6-0.830.54-0.310.66-0.930.990.470.88-0.31-0.860.47
-0.63-0.35-0.39-0.680.330.350.92-0.22-0.25-0.610.56-0.280.41-0.5-0.820.52-0.290.66-0.950.990.510.93-0.28-0.90.51
-0.27-0.44-0.38-0.450.170.360.630.07-0.24-0.530.460.00.14-0.12-0.350.340.00.53-0.410.470.510.530.07-0.491.0
-0.68-0.4-0.39-0.640.290.350.88-0.12-0.25-0.650.45-0.320.31-0.31-0.760.42-0.330.53-0.950.880.930.53-0.36-0.980.53
0.020.020.060.26-0.080.28-0.150.1-0.32-0.3-0.440.55-0.40.490.25-0.340.550.310.33-0.31-0.280.07-0.360.510.07
0.650.450.40.64-0.28-0.28-0.840.090.180.56-0.510.4-0.340.380.76-0.450.4-0.430.94-0.86-0.9-0.49-0.980.51-0.49
-0.27-0.44-0.38-0.450.170.360.630.07-0.24-0.530.460.00.14-0.12-0.350.340.00.53-0.410.470.511.00.530.07-0.49
Click cells to compare fundamentals

Rein Therapeutics Account Relationship Matchups

Rein Therapeutics fundamental ratios Accounts

202020212022202320242025 (projected)
Total Assets16.3M48.5M22.0M106.0M62.2M43.2M
Other Current Liab2.2M3.2M1.6M3.1M4.8M3.3M
Total Current Liabilities4.0M4.5M3.4M4.4M5.7M4.9M
Total Stockholder Equity12.2M43.9M18.6M6.9M54.4M57.1M
Property Plant And Equipment Net15K280K110K19K1K950.0
Net Debt(6.7M)(3.4M)(5.2M)(17.3M)(12.9M)(13.5M)
Retained Earnings(219.3M)(245.5M)(272.8M)(288.5M)(351.4M)(333.8M)
Accounts Payable1.6M1.2M1.7M1.2M911K1.1M
Cash7.0M3.6M5.2M17.3M12.9M10.8M
Non Current Assets Total15K304K134K87.7M48.5M51.0M
Non Currrent Assets Other1.2M568K24K2.2M2K1.9K
Cash And Short Term Investments13.8M45.9M21.2M17.3M12.9M18.0M
Liabilities And Stockholders Equity16.3M48.5M22.0M106.0M62.2M43.2M
Non Current Liabilities Total219K69K0.094.7M47.1M33.7M
Other Current Assets2.5M2.2M631K953K792K1.2M
Other Stockholder Equity231.4M289.3M291.4M295.4M360.7M226.6M
Total Liab4.2M4.6M3.4M99.1M7.8M7.4M
Total Current Assets16.3M48.2M21.9M18.3M13.7M18.9M
Short Term Investments10.1M13.0M6.8M42.3M16.0M0.0
Accumulated Other Comprehensive Income(2K)(13K)(48K)(63K)(18K)(18.9K)
Short Long Term Debt Total387K162K33K48K43.2K41.0K
Short Term Debt168K93K33K48K43.2K41.0K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Rein Stock Analysis

When running Rein Therapeutics' price analysis, check to measure Rein Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rein Therapeutics is operating at the current time. Most of Rein Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rein Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rein Therapeutics' price. Additionally, you may evaluate how the addition of Rein Therapeutics to your portfolios can decrease your overall portfolio volatility.